50个+主要制药公司投资于Treg细胞自免疫疾病治疗,55个治疗处于临床阶段。 50+ major pharma companies invest in Treg cell-based autoimmune disease therapies, with 55 treatments in clinical stages.

针对免疫系统治疗自发免疫疾病的特雷格细胞疗法正在获得牵引力,有50多家大制药公司参与。 Treg cell-based therapies, which target the immune system to treat autoimmune diseases, are gaining traction, with over 50 major pharmaceutical companies involved. 55个以上的疗法处于不同的临床阶段。 More than 55 therapies are in various clinical stages. 值得注意的事态发展包括伙伴关系和指定具体疗法的快车道。 Noteworthy developments include partnerships and Fast Track designations for specific therapies. 编审中报告深入介绍了治疗领域的情况,突出了这个不断扩大的领域的各种机遇和挑战。 The pipeline report offers insights into the therapeutic landscape, highlighting opportunities and challenges within this expanding field.